Aramon Neuro-Medical

Phase III Drug for Treating Severely Ill Parkinsons Patients

Non Active, Apr 2014
Pre-Funding Zikhron Ya'akov, Israel Founded 2013
Last updated 2026-06-18
Total raised
—
Stage
Pre-Funding
Founded
2013
Headcount
6
HQ
Zikhron Ya'akov, Israel
Sector
—

About

Aramon Neuro-Medical develops a new drug formulation administered with a medical device that will be used in patients who are resistant to oral dopamine treatment. This is a problem that currently affects about 10% of Parkinson's patients and is considered to be one of the largest unmet medical needs in the field of Parkinson's disease. Aramon’s compound is a short-acting DA, which physicochemical properties and outstanding potency make it an excellent candidate for continuous subcutaneous (sc) infusion at low doses and volumes. It can be administered by a portable minipump or a patch-pump with daily doses of only about 1mg. This permits a ‘tailor-made’ individualized treatment. It also has strong 5-HT1A agonist effects with anti-dyskinetic properties. Significant and quite relevant improvement in ‘OFF’ time and in dyskinesias has been reported in prospective randomized trials (compared to high-dosed oral L-DOPA) and in this way a sc infusion of the compound avoids the risks of percutaneous enterogastrostomy (PEG), which is necessary for a continuous infusion of L-DOPA, and/or brain surgery (‘Deep Brain Stimulation’, DBS).

Q&A

What is Aramon Neuro-Medical's primary focus?
Aramon Neuro-Medical is focused on developing a Phase III drug for treating severely ill Parkinson's patients, specifically those resistant to oral dopamine treatment.
What is the status of Aramon Neuro-Medical?
Aramon Neuro-Medical is currently inactive, a status it has held since April 2014.
Where is Aramon Neuro-Medical headquartered?
Aramon Neuro-Medical is headquartered in Zikhron Ya'akov, Center District, Israel.
When was Aramon Neuro-Medical founded?
Aramon Neuro-Medical was founded in January 2013.
What is the employee count for Aramon Neuro-Medical?
Aramon Neuro-Medical has 1-10 employees.
What is the product stage of Aramon Neuro-Medical's development?
Aramon Neuro-Medical's product is in the R&D stage.
Does Aramon Neuro-Medical hold any patents?
Yes, Aramon Neuro-Medical holds 1 patent.
What problem does Aramon Neuro-Medical's drug aim to solve?
Aramon Neuro-Medical's drug aims to address the unmet medical need for Parkinson's patients who are resistant to oral dopamine treatment, which affects about 10% of patients.

Sectors & technology

Business model
b2b2c

Highlights

1 Patents

Tags

biotechnologydrug-deliveryparkinsontreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

Identifiers & details

Founded2013-1
Employees (exact)6
Status reasonNon Active, Apr 2014